|Articles|May 1, 2002
Change in daily dosing may hinder treatment effect of glaucoma drug
Patient compliance is a larger problem than physicians like to admit-especially in chronic diseases, such as glaucoma. However, efficacy must not be compromised by the attempt to simplify dosing regimens.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA grants IDE approval to EyeYon Medical for its US clinical study of EndoArt
2
First patient treated in ViaLase’s IDE trial
3
Ocular Therapeutix accelerates NDA submission plans for AXPAXLI for wet AMD
4
Formosa Pharmaceuticals and Rxilient sign licensing and commercialization agreement for APP13007
5











































.png)


